Phase 2
Completed N=294
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
Neuralgia, Postherpetic
Source: ClinicalTrials.gov NCT01129531 ↗
Enrolled (actual)
294
Serious AEs
3.0%
Results posted
Nov 2013
Primary outcomePrimary: Change From Baseline in the Average Pain Intensity Score at Week 12 — 6.13; 6.04; 6.05; -1.42 Score on a scale
Summary
This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in the Average Pain Intensity Score at Week 12 |
6.13; 6.04; 6.05; -1.42; -1.35; -1.27 | — |
| SECONDARY Change From Baseline in Area of Spontaneous Pain |
87.44; 118.17; 98.27; -4.83; -17.18; -6.13 | — |
| SECONDARY Change From Baseline in Area of Allodynia |
184.28; 195.11; 174.17; -32.40; -43.56; -15.27 | — |
| SECONDARY Change From Baseline in Evoked Pain Score in the Area of Allodynia |
60.8; 58.4; 60.0; -11.7; -7.9; -11.1 | — |
Eligibility Criteria
Inclusion Criteria
- Persistent postherpetic neuralgia (PHN) with nerve pain present for at least 9 months after onset of herpes zoster skin rash
Exclusion Criteria
- Female patients with reproductive potential
- Active herpes zoster skin rash
- Current or anticipated treatment with acupuncture, TNS, or steroids
- Current or anticipated use of topical analgesic agents with PHN
- Treatment with botulinum toxin therapy of any serotype within the prior 12 weeks
Data sourced from ClinicalTrials.gov (NCT01129531). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.